Thursday, February 1, 2024

Personal Blog #35 … Biogen is Ending Sale of Aduhelm … 2/1/24

Yesterday, 1/31/24, Biogen announced that it will stop selling Aduhelm, its Alzheimer’s disease (AD) medication, by the end of this year.  When initial approval was given by the Food and Drug Administration (FDA) to market this medication in 2021, FDA required Biogen to conduct additional studies to prove the efficacy of this new drug.  Biogen announced yesterday that it is ending its study needed to obtain full approval from the FDA. 

Readers may remember reading my Personal Blog #23, posted on this site on 6/11/21 … “Letter to Acting FDA Commissioner re Aduhelm.”  In the first paragraph of that PB #23 column, I wrote: “On 6/7/21, the FDA approved the drug Aduhelm, Biogen’s aducanumab medication, an intravenous infusion to be administered monthly for people with Alzheimer’s disease.  Despite not one member of the FDA’s Advisory panel voting to approve this med, FDA approved its use anyway.  FDA determined that since Aduhelm helped clear some amyloid protein from the brain, it may be “expected to help slow dementia.”  However, Biogen’s own data do not support such a claim, and readers can read my Personal Blogs #11 and #12 to learn more about results of clinical trials with this drug.” 

I also wrote the following: “For many patients and caregivers, the high costs of AD medications present an economic hardship. Money spent on (ineffective) AD medications is money that might otherwise be spent on day care programs, companions, home health aides, or other services that would actually improve the quality of their lives.”

“I witnessed AD spouse caregivers having to spend life savings on AD meds.  Some had to sell their homes when placing spouses in assisted living or to cover costs of home health care aides.  Now even more will have to do so because of money needlessly spent on this latest bottle of hope you have approved.  Based upon data I have seen ... a difference of 0.39 on an 18 point scale of cognitive and functional ability ... I can understand why not one member of your 11 member Advisory panel of experts that evaluated the data for FDA voted for approval.”

“I am SO sorry that FDA has approved yet another costly "bottle of hope" that will now financially ruin the lives of more AD spouse survivors with virtually zero benefit to their loved ones.  This is just not fair to people with AD, and not fair to their eventually surviving spouses.”

I also shared an email correspondence I had with Dr. Janet Woodcock, then acting FDA Commissioner.  In one email I had written, “My gripe is that there is no clear evidence that this med will actually slow cognitive decline in a meaningful way.  Unless and until Biogen can produce clear evidence that their medication does slow cognitive decline to a significant extent, it remains only an expensive bottle of hope.”

I also quoted one of several members of the FDA Advisory panel who resigned from the panel in protest, Dr. Aaron Kesselheim, a professor of medicine at Harvard Medical School.  Kesselheim said that FDA’s decision on Biogen “was probably the worst drug approval decision in recent U.S. history … based on the debatable premise that the drug’s effect on brain amyloid was likely to help patients with Alzheimer’s disease.”

In the last paragraph of PB#23, I noted my final comment to acting FDA Commissioner Woodcock re Aduhelm: “I want so much to see a new medication that will truly slow down the progression of the disease to allow a longer period of quality of life.  I want so much to see development of a new medication that will successfully treat if not cure AD.  (But) When an Advisory FDA panel has 11 experts and not even one of those experts votes to approve this medication, one has to wonder how something like this could happen.”

According to yesterday’s report by The Associated Press (AP), about 2,500 people worldwide are currently taking Aduhelm.  The AP report further stated, “Initially priced at $56,000 a year, analysts predicted it would quickly become a blockbuster that would generate billions for Biogen.  Medicare raised the premiums it charges for its coverage partially because of an expected influx of Aduhelm claims.  But doctors were hesitant to prescribe the IV drug, given weak evidence that it meaningfully improved Alzheimer’s patients lives.”

Although it comes as no surprise to me, I am deeply saddened to see yet another much hyped potential AD medication be declared a failure.  I have expressed my concerns about 2 other new AD meds targeting amyloid proteins (plaques) in the brain in Personal Blogs #28, #31 and #32.  These columns expressed my strong views on Lecanemab (now marketed as Leqembi), and Donanemab, a med that the FDA is expected to consider for approval within the next month or two. 

Given Biogen’s failure with Aduhelm, I can only reiterate what I wrote in last month’s PB #34.  Until science discovers exactly what causes AD … and as of today there is no definitive proof that AD is caused by the build-up of amyloid proteins in the brain … it will be extremely difficult if not impossible to develop a medication that can prevent AD or treat AD effectively.

 

 

 

 

Sunday, January 14, 2024

Personal Blog #34 … Will 2024 Be the Year We Finally Discover the Cause(s) of Alzheimer’s Disease? … 1/14/24

I didn’t know much about Alzheimer’s back in 2007, but that was the year when I started searching the Internet for reasons to explain why, in my opinion, my wife was exhibiting worrisome behaviors.  Nobody else seemed to be noticing those behaviors, but I was seeing them more and more.  I continued worrying, I continued educating myself, and by early 2008 I was convinced that my wife was already dealing either with Mild Cognitive Impairment (MCI) or the early stages of Alzheimer’s disease (AD). 

Although my wife saw no reason to do so, I was able to convince her to see a neurologist after we returned from a particular trip in 2007.  During that trip, my wife exhibited many worrisome behaviors.  She was forgetting simple things (like our hotel room number or the names of our children and grandchildren), losing and misplacing things (leaving her sweater, coat, camera, and pocketbook in hotel rooms and restaurants) and was frequently disoriented when visiting sites in cities. 

My wife and I had recently entered our 60s and, like many friends our age, we were already starting to have those occasional “senior moments” when we’d forget something we knew well.  But my wife getting us lost on a regular basis was a major worrisome behavior.  I always got lost because I have no sense of direction, but I had always relied upon my wife’s “built-in GPS system” that, until that trip, had always guided us correctly wherever we were.  On that 2007 trip, however, even I knew she was repeatedly leading us in the wrong direction, we were frequently lost, and I, the one with no sense of direction, had to somehow lead us back to the correct location.

Throughout the rest of that year and in 2008, my wife’s doctors … first just our internist, and then the neurologist … saw no signs of MCI or AD.  They were both treating her first for stress, then for anxiety, and then for depression.  Throughout that time, I could not get my wife to agree to see another doctor for a second opinion, and each time I’d bring up that suggestion she would scream at me saying it was unnecessary.  Towards the end of 2008 and into early 2009, the neurologist suggested that my wife also be seen weekly by a clinical psychologist to help her with “coping mechanisms.”

At home I was regularly seeing new worrisome behaviors emerge, but none of my wife’s doctors observed these behaviors and all of her cognitive testing (MMSE tests, mostly) and brain scans seemed to be normal.  Despite what the doctors told me, I was now totally convinced that my wife was in the early stages of AD based upon all of my online reading from highly reputable governmental sites (such as NIA, NIH, and CDC), hospital sites (such as Mayo Clinic, Johns Hopkins, and Cleveland Clinic) and organizational sites (such as the Alzheimer’s Association, Fisher’s Center for Alzheimer’s Research Foundation, and UsAgainstAlzheimer’s).

In early 2009, feeling very frustrated that my wife was not properly diagnosed and was not being treated properly, I confronted the clinical psychologist.  I asked that if it were his wife being treated for more than a year for stress, anxiety, depression… and was actually getting worse … would he take his wife for a 2nd opinion?  The psychologist said he had just spoken that morning with my wife’s neurologist.  I cut him off in mid-sentence, saying I had no faith in that neurologist.  I again repeated, would he take his wife for a 2nd opinion?  The psychologist, now red-faced, said yes.  I turned to my wife and asked, “Now can I take you for a 2nd opinion?”  She said “yes.”

Within a month my wife was seen by a geriatric psychiatrist affiliated with an Alzheimer’s Disease Research Center.  After just two lengthy visits and many hours of bloodwork, interviews, cognitive testing (not just the MMSE, but many tests), and new brain scans … and lengthy interviews of me to determine behaviors I was witnessing …  my wife was diagnosed with early onset AD.  Within a month my wife was taking Aricept, enrolled in a promising clinical trial, and my frustrations eased considerably because I now felt (in retrospect, naively so) that my wife was finally being treated effectively.

It has now been 15 years since my wife’s diagnosis in 2009.  What have we learned about the cause or causes of AD in those 15 years?  Sadly, the short answer is … not all that much.

Fifteen years ago I learned about amyloid-beta proteins (plaques) and tau proteins (tangles) and noted that most AD research money flowed into projects intended to definitively determine how one of both of those proteins were the cause(s) of AD.  Unfortunately, here we are in 2024 and we still haven’t conclusively determined if that is true, and at this stage many researchers are wondering if the presence of amyloid proteins may the results of AD rather than the cause.

Based upon a 2022 study at the University of Cincinnati, the chief neurologist and his research colleagues “hypothesized that plaques are simply a consequence of the levels of soluble amyloid-beta in the brain decreasing. The paradox is that so many of us accrue plaques in our brains as we age, and yet so few of us with plaques go on to develop dementia.” 1

The latest statement from CDC, the Centers for Disease Control and Prevention, states the following: “Scientists do not yet fully understand what causes Alzheimer’s disease. There likely is not a single cause but rather several factors that can affect each person differently.” 2 

CDC does note some risk factors for AD  and several of those are listed on the CDC site.  Unfortunately, people have no control over the number one risk factor … age.  As we have long known, “Age is the best known risk factor for Alzheimer’s disease.”   All other risk factors noted by CDC are either ones we cannot control (e.g., family history) or statements with caveats such as, “a healthy life style may (my emphasis added) play a role in developing AD.” 2

The NIA, National Institute of Aging, notes the following on its site: “In recent years, scientists have made tremendous progress in better understanding Alzheimer’s and the momentum continues to grow. Still, scientists don’t yet fully understand what causes Alzheimer’s disease in most people.” 3  The NIA site suggests something similar to what is on the CDC site.  In its section, “What causes AD,” The NIA page has the following statement: “The causes probably (my emphasis added) include a combination of age-related changes in the brain, along with genetic, environmental, and lifestyle factors. 3

Similar non-emphatic statements can be found on just about any reputable site.  According to the Mayo Clinic, “The exact causes of Alzheimer's disease aren't fully understood … Scientists believe (my emphasis added) that for most people, Alzheimer's disease is caused by a combination of genetic, lifestyle and environmental factors that affect the brain over time.” 4

Organization websites, such at that of the Alzheimer’s Association, say something similar: “Researchers believe there isn't a single cause of Alzheimer's disease. It likely (my emphasis added) develops from multiple factors, such as genetics, lifestyle and environment. Scientists have identified factors that increase the risk of Alzheimer’s. While some risk factors — age, family history and heredity — can't be changed, emerging evidence suggests there may (my emphasis added) be other factors we can influence.” 5

So, whereas we have made some progress in learning about AD in these past 15 years, we still haven’t learned what causes AD.  It is extremely difficult to effectively prevent or treat a disease when we do not know the cause(s).  We are basically proceeding with common-sense advice that seems rational … that a healthy life style of eating nutritious foods, regularly exercising, avoiding brain injuries, etc. may (my emphasis added) prevent some (my emphasis added) people from developing AD.  But, as of today, we do not know that for sure.

It is too late for my wife, who died in 2016, and millions of others who have passed away directly because of AD or with AD as a major contributing factor.  Although continually listed among the top 10 causes of death in this country, the number of people dying with or because of AD is considered significantly greater than what is reported on death certificates.  According to the Alzheimer’s Association, “Death certificates for individuals with Alzheimer’s often list acute conditions such as pneumonia as the primary cause of death rather than Alzheimer’s … even though Alzheimer’s disease may well have caused the acute condition listed on the death certificate.” 6

When I received the death certificate from the nursing home after my wife’s death, I was shocked to note that AD was not mentioned as either the direct cause or as a contributing cause. 7   When I asked the nursing home doctor why, his response was that he couldn’t prove that AD was the cause.  When I asked why he didn’t even include AD as a contributing cause, he said he couldn’t prove that either. 

Therefore, 2016 CDC mortality statistics for deaths due to AD in the U.S. did not include my wife’s death.  On page 6 of its 2016 report on mortality rates, CDC listed AD as the 6th leading cause of death in this country in 2016. 8   On page 62 of that same CDC report, the following statement appears: “Quality of mortality data is largely dependent on proper and thorough completion of death certificates by certifiers. Accuracy and completeness of information entered on death certificates can vary by state from year to year.” 8   One can only wonder how many thousands of deaths in this country due in whole or part to AD each year have not been reported accurately on death certificates.

I hope our government continues to increase funding for AD research in hopes of finding an effective means of prevention or cure.  In 2009, the NIH allocated $457 million for AD research. 9   I am very pleased to note that estimated NIH funding for AD research proposed for 2024 is approximately $3.5 billion. 10   Hopefully, increased federal spending will result in promising research and discovery.

Discovering a definitive way to prevent AD is the goal, but I’d be very happy if we can just learn how to more effectively treat this disease.  Recent medications approved by the FDA to help those with AD do not excite me.  In fact, if my wife were still alive, I doubt whether she or I would have wanted her to take any of these new medications. 11   

But even if AD remains a death sentence with no cure, treatment that can enable people with AD to maintain and enjoy a high quality for life for 10, 15, or 20 years after diagnosis would be a wonderful advance. 

Maybe 2024 will be the year when this happens.

1.  Tedeschi, Tim. UC study: Decreased proteins, not amyloid plaques, tied to Alzheimer’s disease.  Accessed on January 14, 2024.  https://www.uc.edu/news/articles/2022/09/decreased-proteins-not-amyloid-plaques-tied-to-alzheimers.html

2.  Alzheimer’s Disease and Healthy Aging.  Centers for Disease Control and Prevention.  Accessed on January 14, 2024.  https://www.cdc.gov/aging/alzheimers-diseasedementia/aboutalzheimers.html#:~:text=Scientists%20do%20not%20yet%20fully,risk%20factor%20for%20Alzheimer's%20disease.

3.  What causes Alzheimer’s disease?  Accessed on January 14, 2024.    https://www.nia.nih.gov/health/alzheimers-and-dementia/alzheimers-disease-fact-sheet 

4.  Alzheimer’s disease.  Mayo Clinic.  Accessed on January 14, 2024.  https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/symptoms-causes/syc-20350447

5.  Causes and Risks for Alzheimer’s disease.  Alzheimer’s Association.  Accessed on January 14, 2024.  https://www.alz.org/alzheimers-dementia/what-is-alzheimers/causes-and-risk-factors

6. 2023 Alzheimer’s Disease Facts and Figures.  Alzheimer’s Association.  Accessed on January 14, 2024, p. 35.  https://www.alz.org/media/documents/alzheimers-facts-and-figures.pdf

7.  Vann, Allan S.  Reporting Deaths of Patients with Alzheimer’s.  Journal of the American Geriatrics Society.  December, 2016. 64:12, pp. 2419-2420.

8. Deaths: final data for 2016, July 26, 2018.  Centers for Disease Control and Prevention.  Accessed on January 14, 2024.  https://stacks.cdc.gov/view/cdc/57989

9.  Research Priority Setting, and Funding Allocations across Selected Diseases and Conditions.  National Institutes of Health.  Accessed on January 14, 2024.   https://www.gao.gov/assets/gao-14-246.pdf

10.  Estimates of Funding for Various Research, Condition, and Disease Categories (RCDC).  NIH RePORT.  Accessed on January 14, 2024.  https://report.nih.gov/funding/categorical-spending#/

11.  Vann, AS. ”Reflections of An Alzheimer’s Spouse.”  Personal Blog columns # 28, 31, and 32 discuss recent medications approved by the FDA within the past 2 years.  https://allansvann.blogspot.com/